Chamseddine Shadi, LaPelusa Michael, Xiao Lianchun, Mohamed Yehia I, Lee Sunyoung S, Hu Zishuo Ian, Hatia Rikita I, Hassan Manal, Yao James C, Duda Dan G, Datar Saumil, Amin Hesham M, Kaseb Ahmed O
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Hepatocell Carcinoma. 2024 Mar 4;11:455-461. doi: 10.2147/JHC.S452564. eCollection 2024.
In this study, we explored the potential of plasma growth hormone (GH) as a prognostic biomarker in patients with advanced HCC treated with durvalumab plus tremelimumab (D+T).
In this study, we included 16 patients with advanced HCC who received D+T at MD Anderson Cancer Center between 2022 and 2023 and had plasma GH measurements recorded before treatment. Plasma GH levels were measured from prospectively collected blood samples and were correlated with progression-free survival (PFS) and overall survival (OS). The cutoff for normal GH levels in women and men was defined as ≤3.7 μg/L and ≤0.9 μg/L, respectively. The Kaplan-Meier method was employed to compute the median OS and PFS, while the Log rank test was applied to compare the survival outcomes between the GH-high and GH-low groups.
Sixteen patients were included in this analysis, two female and fourteen male, with a median age of 65.5 years. At the time of the analysis, the 6-month OS rate was 100% among GH-low patients (6 patients) and 30% among GH-high patients (10 patients). OS was significantly longer in GH-low patients (not evaluable) compared to GH-high patients (3.94 months) (p = 0.030). PFS was also significantly longer in GH-low patients (not evaluable) compared to the GH-high patients (1.87 months) (p = 0.036).
Plasma GH is a prognostic biomarker in patients with advanced HCC treated with D+T. Given the relatively small patient cohort size, this finding should be further validated in larger randomized clinical trials in advanced HCC patients.
在本研究中，我们探讨了血浆生长激素（GH）作为接受度伐利尤单抗联合曲美木单抗（D+T）治疗的晚期肝癌患者预后生物标志物的潜力。
本研究纳入了16例晚期肝癌患者，这些患者于2022年至2023年在MD安德森癌症中心接受了D+T治疗，并在治疗前记录了血浆GH测量值。从前瞻性收集的血样中测量血浆GH水平，并将其与无进展生存期（PFS）和总生存期（OS）相关联。女性和男性正常GH水平的临界值分别定义为≤3.7μg/L和≤0.9μg/L。采用Kaplan-Meier方法计算中位OS和PFS，同时应用对数秩检验比较GH高组和GH低组之间的生存结果。
本分析纳入了16例患者，其中2例女性，14例男性，中位年龄为65.5岁。在分析时，GH低组（6例患者）的6个月OS率为100%，GH高组（10例患者）为30%。与GH高组患者（3.94个月）相比（p=0.030），GH低组患者的OS显著更长（不可评估）。与GH高组患者（1.87个月）相比（p=0.036），GH低组患者的PFS也显著更长（不可评估）。
血浆GH是接受D+T治疗的晚期肝癌患者的预后生物标志物。鉴于患者队列规模相对较小，这一发现应在晚期肝癌患者的更大规模随机临床试验中进一步验证。
